Trial Profile

REAL WORLD DATA COLLECTION AMONG PEDIATRIC NEUROBLASTOMA PATIENTS TREATED WITH LORLATINIB THROUGH EXPANDED ACCESS PROGRAM

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Neuroblastoma
Focus Adverse reactions; Expanded access; Therapeutic Use
Sponsors Pfizer

Most Recent Events

15 Mar 2023 Status changed from completed to discontinued due to operational implementation challenges and insufficient collection of key data due to varied data accessibility across global study sites.
17 Nov 2022 Status changed from recruiting to completed.
19 May 2021 Planned End Date changed from 5 Mar 2026 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com